Skip to main content
Premium Trial:

Request an Annual Quote

The Company's Gone, But What About the Data?

Inspired by the financial problems at TruGenetics and DeCode, a guest post at Genetic Future from Genomics Law Report's Daniel Vorhaus and Lawrence Moore discusses what happens when a direct-to-consumer genomics company goes out of business. In particular, they take a look at the company's privacy and confidentiality policies. What will become of the users' data comes down to that fine print. Vorhaus and Moore conclude:

If the company's policy clearly permits the sale of genomic information in the kind of transaction that could be consummated in a bankruptcy case, then such a sale can go forward. But if the policy prohibits such a sale, or if the policy is unclear or does not address the subject at all, a transfer may still take place.
The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.